Holen Sie sich die Stockscreener-App
26.13
0.53%
-0.14
Handel nachbörslich:
26.13
Schlusskurs vom Vortag:
$26.27
Offen:
$26.25
24-Stunden-Volumen:
370.90K
Relative Volume:
0.82
Marktkapitalisierung:
$1.11B
Einnahmen:
$720.53M
Nettoeinkommen (Verlust:
$79.23M
KGV:
15.70
EPS:
1.6648
Netto-Cashflow:
$132.94M
1W Leistung:
+10.63%
1M Leistung:
+18.88%
6M Leistung:
+33.52%
1J Leistung:
-0.87%
1-Tages-Spanne:
$25.66
$26.63
1-Wochen-Bereich:
$23.45
$26.63
52-Wochen-Spanne:
$16.64
$29.52
Amphastar Pharmaceuticals Inc Stock (AMPH) Company Profile
Firmenname
Amphastar Pharmaceuticals Inc
Sektor
Telefon
909-980-9484
Adresse
11570 SIXTH STREET, RANCHO CUCAMONGA, CA
Compare AMPH vs TAK, TEVA, HLN, ZTS, VTRS
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
AMPH
Amphastar Pharmaceuticals Inc
|
26.13 | 1.11B | 720.53M | 79.23M | 132.94M | 1.6648 |
TAK
Takeda Pharmaceutical Co Adr
|
18.86 | 60.23B | 29.91B | 1.30B | 3.49B | 0.4056 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
39.19 | 45.71B | 17.53B | 1.58B | 444.18M | 1.3457 |
HLN
Haleon Plc Adr
|
9.26 | 40.72B | 14.54B | 2.22B | 2.58B | 0.4871 |
ZTS
Zoetis Inc
|
71.05 | 29.36B | 9.51B | 2.64B | 2.14B | 6.0361 |
VTRS
Viatris Inc
|
17.83 | 20.48B | 14.57B | -296.50M | 1.64B | -0.259 |
Amphastar Pharmaceuticals Inc Stock (AMPH) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-04-21 | Herabstufung | Jefferies | Buy → Hold |
| 2025-12-09 | Eingeleitet | Barclays | Equal Weight |
| 2025-08-12 | Hochstufung | Needham | Hold → Buy |
| 2025-05-12 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2025-02-04 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2024-11-22 | Eingeleitet | Wells Fargo | Equal Weight |
| 2024-03-05 | Eingeleitet | JP Morgan | Overweight |
| 2023-11-17 | Eingeleitet | BofA Securities | Neutral |
| 2023-07-25 | Fortgesetzt | Jefferies | Buy |
| 2022-10-21 | Fortgesetzt | Jefferies | Buy |
| 2022-07-29 | Eingeleitet | CapitalOne | Overweight |
| 2022-01-07 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2021-01-08 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2020-10-05 | Hochstufung | Northland Capital | Market Perform → Outperform |
| 2020-05-01 | Eingeleitet | Northland Capital | Outperform |
| 2019-03-13 | Herabstufung | Needham | Buy → Hold |
| 2019-03-13 | Herabstufung | Piper Jaffray | Overweight → Neutral |
| 2018-08-10 | Bestätigt | Needham | Buy |
| 2018-03-13 | Bestätigt | Needham | Buy |
| 2017-12-01 | Bestätigt | Needham | Buy |
| 2017-11-09 | Herabstufung | Raymond James | Outperform → Mkt Perform |
| 2017-09-27 | Bestätigt | Needham | Buy |
| 2017-03-14 | Herabstufung | Raymond James | Strong Buy → Outperform |
| 2016-08-09 | Bestätigt | Needham | Buy |
| 2016-05-10 | Bestätigt | Needham | Buy |
| 2016-02-19 | Eingeleitet | Wells Fargo | Outperform |
| 2015-06-19 | Bestätigt | Needham | Buy |
| 2015-06-03 | Eingeleitet | Raymond James | Strong Buy |
| 2014-07-21 | Eingeleitet | Needham | Buy |
Alle ansehen
Amphastar Pharmaceuticals Inc Aktie (AMPH) Neueste Nachrichten
Is It Too Late to Buy Amphastar Pharmaceuticals Inc (AMPH) After 5.2% Rally? GF Value Says Undervalued - GuruFocus
Amphastar Pharmaceuticals, Inc. (AMPH) Stock Price, News, Quote & History - Yahoo! Finance Canada
Amphastar Pharmaceuticals, Inc. (AMPH) Stock Forecasts - Yahoo Finance
Insider Selling: Amphastar Pharmaceuticals (NASDAQ:AMPH) CFO Sells 4,139 Shares - MarketBeat
At $25 a share, Amphastar Pharmaceuticals (AMPH) CFO William Peters sold 4,139 shares. - Stock Titan
Amphastar (NASDAQ: AMPH) exec plans 4,139-share Rule 144 sale - Stock Titan
Amphastar Pharmaceuticals, Inc. (AMPH) Stock forecasts - Yahoo Finance UK
Amphastar Pharmaceuticals (NASDAQ:AMPH) EVP Rong Zhou Sells 10,000 Shares of Stock - MarketBeat
Amphastar Pharmaceuticals (NASDAQ:AMPH): Strongest Q2 Results from the Generic Pharmaceuticals Group - finance.yahoo.com
Squarepoint Ops LLC Has $1.59 Million Stock Holdings in Amphastar Pharmaceuticals, Inc. $AMPH - MarketBeat
Amphastar Pharmaceuticals (NASDAQ:AMPH) Lowered to "Buy" Rating by Wall Street Zen - MarketBeat
Legal & General Group Plc Makes New $1.58 Million Investment in Amphastar Pharmaceuticals, Inc. $AMPH - MarketBeat
Amphastar Pharmaceuticals (AMPH) Rebounds In Focus, Is It Slightly Overvalued? - Yahoo Finance
Bank of New York Mellon Corp Makes New Investment in Amphastar Pharmaceuticals, Inc. $AMPH - MarketBeat
Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) Receives Consensus Recommendation of "Reduce" from Analysts - MarketBeat
Amphastar Pharmaceuticals (AMPH) Stock Looks Cheap With Earnings Doing The Heavy Lifting - Yahoo Finance
Rong Zhou Sells 3,187 Shares of Amphastar Pharmaceuticals (NASDAQ:AMPH) Stock - MarketBeat
Insider sells 3,187 shares at Amphastar (NASDAQ: AMPH) - Stock Titan
A Look at Amphastar Pharmaceuticals Inc (AMPH) After 3.3% Gain -- GF Value $35.96 vs Price $23.74 - GuruFocus
Empowered Funds LLC Invests $3.29 Million in Amphastar Pharmaceuticals, Inc. $AMPH - MarketBeat
Amphastar (NASDAQ: AMPH) VP plans Rule 144 stock sale led by 10,000-share option exercise - Stock Titan
Amphastar Pharmaceuticals to Present at the Wells Fargo 21st Annual Healthcare Conference - Stock Titan
Zacks Industry Outlook Highlights Amphastar Pharmaceuticals, Sandoz and Viatris - Yahoo Finance
Bank of America Corp DE Acquires 46,149 Shares of Amphastar Pharmaceuticals, Inc. $AMPH - MarketBeat
Amphastar Pharmaceuticals, Inc. $AMPH Stock Holdings Lifted by Algert Global LLC - marketbeat.com
Amphastar Pharmaceuticals (NASDAQ:AMPH) Stock Price Passes Above 50-Day Moving AverageShould You Sell? - marketbeat.com
Analysts Estimate Amphastar Pharmaceuticals (AMPH) to Report a Decline in Earnings: What to Look Out for - Eastern Progress
Amphastar Pharmaceuticals Earnings Call Balances Growth And Risk - TipRanks
Denali Advisors LLC Has $7.59 Million Position in Amphastar Pharmaceuticals, Inc. $AMPH - MarketBeat
Amphastar (AMPH) Quarterly Results: EPS Exceeds Its Estimate in Latest Trading; Trading Response: The Stock Ends Up 2.30% on the DayEarnings Weakness Phase - Vinanet
Amphastar (NASDAQ: AMPH) insider lines up stock sale after option exercise - Stock Titan
Barclays Issues Positive Forecast for Amphastar Pharmaceuticals (NASDAQ:AMPH) Stock Price - MarketBeat
Barclays Adjusts Price Target on Amphastar Pharmaceuticals to $23 From $20, Maintains Equalweight Rating - marketscreener.com
Is It Too Late to Buy Amphastar Pharmaceuticals Inc (AMPH) After 3.6% Rally? GF Value Says Undervalued - GuruFocus
Lead Independent Director Richard Prins Sold A Bunch Of Shares In Amphastar Pharmaceuticals - simplywall.st
The Top 5 Analyst Questions From Amphastar Pharmaceuticals’s Q2 Earnings Call - Yahoo Finance
Amphastar Pharmaceuticals (AMPH) Director Richard Prins Sells 7, - GuruFocus
Richard Prins Sells 7,973 Shares of Amphastar Pharmaceuticals (NASDAQ:AMPH) Stock - MarketBeat
Amphastar director Richard Prins disposes of shares valued at $161,851 By Investing.com - Investing.com South Africa
Amphastar director Richard Prins disposes of shares valued at $161,851 - Investing.com
Director Richard Prins sells 7,973 Amphastar (AMPH) shares at $20.30 - Stock Titan
Amphastar CFO William Peters sells $183,886 in company stock - Investing.com
Enterprise value to EBITDA forward of Amphastar Pharmaceuticals, Inc. – MUN:29A - TradingView
Amphastar Pharmaceuticals (NASDAQ:AMPH) CFO William Peters Sells 8,180 Shares - MarketBeat
Amphastar (AMPH) CFO exercises options and sells 8,180 shares in 10b5-1 trade - Stock Titan
AMPH (AMPH) schedules Rule 144 stock sale tied to RSU vesting - Stock Titan
Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) Receives Average Recommendation of "Reduce" from Analysts - MarketBeat
Weekly Recap: Amphastar Q2 growth, $100M BAQSIMI and IMS FDA warning - TradingView
Results: Amphastar Pharmaceuticals, Inc. Exceeded Expectations And The Consensus Has Updated Its Estimates - Moomoo
Amphastar Pharmaceuticals (AMPH) Stock Rebound Meets Margin Pressure And Valuation Gap - Sahm
Amphastar Pharmaceuticals (NASDAQ:AMPH) Upgraded by Wall Street Zen to "Strong-Buy" Rating - MarketBeat
Finanzdaten der Amphastar Pharmaceuticals Inc-Aktie (AMPH)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.18%
0.69%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):